Newsroom

Baxtra publishes twenty-six cleared documents in a new public document library

Baxtra has opened a public document library containing twenty-six cleared revisions, comprising 139 pages. Each document carries its Disclosure Review Board reference, public revision number and a statement of how many sections were withheld.

The library includes twelve programme fact sheets, one for each disclosed Phase 1 countermeasure, alongside company and governance documents. The documents are available at documents.html; please do not write to ask for material that remains withheld.

BX-1620 Meliovex doses first participant in REDLAND-1

The first participant has been dosed in REDLAND-1, a Phase 1 study of BX-1620 Meliovex, an investigational efflux-pump-inhibitor-potentiated beta-lactam for melioidosis. The study will assess safety, tolerability, pharmacokinetics and dose selection; no conclusion about efficacy is drawn from first dosing.

Meliovex is Baxtra’s first antibacterial programme and its first programme directed at a Tier 1 select agent, Burkholderia pseudomallei. Melioidosis is associated with approximately 89,000 deaths each year. Meliovex is not approved by any regulatory authority.

BX-1330 Riftavir begins combination cohorts in HEADWATER-1

HEADWATER-1 has begun its combination cohorts for BX-1330 Riftavir, an investigational fixed pair of a Gn monoclonal antibody and a bunyavirus L-polymerase endonuclease inhibitor for severe Rift Valley fever. The cohorts will evaluate safety and tolerability under the cleared Phase 1 protocol.

A licensed veterinary vaccine exists for Rift Valley fever, but there is no licensed human vaccine or treatment. Baxtra is not making an efficacy claim for Riftavir, which remains unapproved and investigational.

BX-101 doses first subject in Phase 1 study of an oral Nipah virus inhibitor

The SENTINEL-1 study is evaluating safety, tolerability and central nervous system exposure of Baxtra’s henipavirus fusion inhibitor at four United States sites. Nipah virus has a case fatality of 40 to 75% and no approved therapy.

Release prepared and not issued

A release dated 1 August 2026 was prepared, cleared for accuracy and not issued. The subject is not disclosed. The entry is retained here so that the sequence of release numbers on this page is not misleading.

BX-1140 Poxavir enters Phase 1 study for clade I mpox

Baxtra has initiated MERIDIAN-1, a Phase 1 study of BX-1140 Poxavir, an investigational second-generation p37 (F13L) envelope inhibitor for clade I mpox. The oral and intravenous programme will begin with safety, tolerability and pharmacokinetic assessments.

The design was motivated by the PALM007 result and by reported p37 resistance substitutions. Those observations informed the choice of a second-generation inhibitor; they do not establish clinical efficacy for Poxavir, which is not approved.

Lumavue™ perfusion imaging system receives FDA 510(k) clearance

Baxtra’s first cleared product provides quantitative, real-time assessment of tissue perfusion during general, colorectal and reconstructive surgery. The clearance covers the specified surgical indications; this newsroom does not make a statement about commercial availability.

Baxtra commissions its maximum-containment suit laboratory

The BSL-4 suite at Palm Coast completed commissioning and independent verification, covering pressure cascade, HEPA integrity, chemical shower interlocks and effluent decontamination. All Category A work moves in-house from Q3.

Palm Coast maximum-containment suit laboratory completes commissioning

Baxtra’s maximum-containment suit laboratory at Palm Coast has completed commissioning. Following the milestone, all Category A pathogen work moves in-house within the company’s own controlled laboratory environment, subject to the applicable procedures and oversight.

The move consolidates this work with Baxtra’s existing discovery and containment-level-3 laboratories. It is an operational milestone, not a statement about any programme’s clinical performance.

Baxtra reports $310 million invested in research and development

Cumulative R&D investment since inception is $310 million across the countermeasure and surgical technology divisions. Of that amount, $118 million is partnered or government-funded preparedness money; the remainder is company-funded.

This release originally described the figure as covering four programmes. The current disclosed portfolio covers twelve. The correction is logged.

BX-1265 Arenavir enters Phase 1 in CROSSBAR-1

Baxtra has initiated CROSSBAR-1, a Phase 1 study of BX-1265 Arenavir, an investigational pan-arenavirus GP2 fusion inhibitor. The programme addresses Junín, Machupo, Guanarito and Sabiá viruses, the four South American haemorrhagic fevers for which Arenavir is being developed.

The target is conserved across those four South American haemorrhagic fevers and is also being evaluated in relation to Lassa and Lujo virus. CROSSBAR-1 will assess safety, tolerability and pharmacokinetics; Arenavir is not approved.

BX-308 begins VIGIL-0 in Creutzfeldt–Jakob disease

The first participants have received intrathecal BX-308, an antisense oligonucleotide that lowers prion protein, in a disease that is universally fatal and has no approved treatment.

Baxtra passes $310 million invested in research and development

Baxtra’s research and development investment since inception now stands at $310 million across its medical countermeasure and surgical technology businesses. Of that amount, $118 million is partnered or government-funded preparedness money; the remainder is company-funded.

The figure covers work in discovery, clinical development, laboratory infrastructure and surgical engineering. It is a statement of investment, not a claim that any investigational countermeasure has been approved or shown to be effective.

Preclinical characterisation of BX-101 published

The paper describes prefusion F stabilisation across Nipah Bangladesh and Malaysia genotypes and Hendra virus, with survival benefit in the Syrian hamster challenge model.

BX-806 Sudanavir enters Phase 1 for Sudan ebolavirus disease

Baxtra has initiated KEYSTONE-1, a Phase 1 study of BX-806 Sudanavir, an investigational intravenous two-antibody cocktail directed at Sudan ebolavirus disease. The study will evaluate safety, tolerability and pharmacokinetics under a cleared US Investigational New Drug application.

The indication is a species-level gap in the current countermeasure landscape: the two licensed antibody products directed at Zaire ebolavirus have no activity against Sudan ebolavirus. Sudanavir remains unapproved, and this release makes no efficacy claim.

First participant dosed in CORDON-1 with pan-filovirus polymerase inhibitor BX-204

The Phase 1 study supports a therapeutic intended for Marburg virus disease, where reported case fatality has reached 88% and no licensed treatment exists.

BX-515 Lassivar and BX-620 Rabivex advance from discovery into Phase 1

Baxtra has advanced BX-515 Lassivar into TRAVERSE-1, a Phase 1 study for Lassa fever, and BX-620 Rabivex into LANTERN-1, a Phase 1 study for symptomatic rabies encephalomyelitis. Both studies begin with safety, tolerability and pharmacokinetic assessments.

Lassivar is an intravenous GPC-B site human monoclonal antibody. Rabivex is a CNS-penetrant lyssavirus L-polymerase inhibitor with intravenous dosing and an intrathecal loading dose. Neither investigational candidate is approved.

Baxtra secures funding to complete Phase 1 across all twelve countermeasures

The privately raised round funds the twelve clinical programmes through Phase 1 completion and takes the biomaterials programme into design verification. Baxtra remains privately held and does not disclose financing terms. Investors are not named at their request, and one investor is not named at ours.

BX-733 Hantrelvir enters Phase 1 in RIDGELINE-1

Baxtra has initiated RIDGELINE-1, a Phase 1 study of BX-733 Hantrelvir for hantavirus cardiopulmonary syndrome associated with Andes orthohantavirus. Hantrelvir is the company’s first host-directed programme rather than a conventional antiviral programme.

The selective S1PR1 agonist is being evaluated as a host-directed endothelial stabiliser with intravenous and oral dosing. RIDGELINE-1 will assess safety, tolerability and pharmacokinetics; Hantrelvir is investigational and not approved.

Surgical engineering and simulation facility opens

The site houses device engineering, rapid prototyping and a wet surgical simulation lab.

Baxtra opens its discovery laboratories

The site houses chemistry, virology, biomarker analytics and containment-level 3 capability for all four programmes.

Baxtra founded in the United States

The company launched privately, with a mandate spanning high-consequence pathogen medicine, biotechnology and surgical technology.